SABCS 2023

Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to share our latest scientific and clinical research findings during the San Antonio Breast Cancer Symposium 2023.

Schedule a meeting with us

Product Theater
Poster Presentations

Product Theater

December 7, 2023

live session

Time
2:15–3:15pm CT

Location
Product Theater B

Presenters
Calvin Chao, MD, Senior Vice President of Medical Affairs at Tempus; Rebecca Shatsky, MD, Professor of Medicine, UC San Diego Health

Integrating AI-Enabled Technology and Comprehensive Molecular Profiling to Enhance Breast Cancer Care

Explore the latest advancements for enabling precision oncology as we discuss recent research findings, breakthroughs in molecular profiling, the expansion of our liquid biopsy portfolio and the impact AI-enabled technological innovations have on reshaping the advanced breast cancer landscape. Join us to gain essential insights and be a part of the evolution of personalized breast cancer patient care.

Poster Presentations

December 7, 2023

live session

Time
7:00–8:00am CT

Presentation Information
PS10-04
Poster+Spotlight Discussion
Ballroom 3-4

The Landscape of Somatic Genetic Alterations in Breast Cancers from Carriers of Germline Pathogenic Variants in DNA-repair Genes

Authors
Siddhartha Yadav (Mayo Clinic), Ali Arafa (University of Minnesota), Emily Teslow (Tempus), Minxuan Huang (Tempus), Melissa Stoppler (Tempus), Calvin Chao (Tempus), Emmanuel Antonarakis (University of Minnesota), Fergus Couch (Mayo Clinic)

Utilizing the Tempus multimodal real-world database, the research team assessed the landscape of somatic alterations in breast cancer patients with hereditary pathogenic variants in five DNA-repair genes compared to those with sporadic breast tumors. The observed frequencies of CCND1, ESR1, PIK3CA, FGFR1, and TP53 alterations differed between these patient groups, breast cancer subtypes, and the pathogenic hereditary gene indicating there may be underlying differences in tumorigenesis for patients with hereditary breast cancer.

live session

Time
12:00–2:00pm CT

Presentation Information
PO3-23-09
Poster Session 3

ESR1 Mutations Drive Resistance to CDK4/6 Inhibitors In ER+ Breast Cancer

Authors
Rosario Chica-Parrado (UT Southwestern), Chang-Ching Lin (UT Southwestern), Ellen Jaeger (Tempus), Michelle Harris (Tempus), Lei Guo (UT Southwestern), Emmanuel Bikorimana (UT Southwestern), Fabiana Napolitano (UT Southwestern), Calvin Chao (Tempus), Ariella Hanker (UT Southwestern), Carlos Arteaga (UT Southwestern)

In order to identify if ESR1 mutations drive resistance to CDK4/6 inhibitors (CDK4/6i) in ER+/HER2- breast cancer (BC), the research team leveraged Tempus’ multimodal real-world data to stratify ER+ BC patients treated with or without a CDK4/6i. They found that ESR1 mutations were enriched in patients treated with a CDK4/6i in a cohort of 3,958 patients with ER+/HER2- metastatic BC. Additionally, the team utilized in vitro and in vivo models, along with RNA-seq, to demonstrate that known ESR1 gain-of-function mutations were sufficient to confer resistance to CDK4/6 inhibitors.

December 8, 2023

live session

Time
12:00–2:00pm CT

Presentation Information
PO5-24-03
Poster Session 5

Breast Cancer Intrinsic Subtypes Predict Outcomes In Primary And Metastatic Samples

Authors
Talal Ahmed (Tempus), Mark Carty (Tempus), Kaverni Nadhamuni (Tempus), Raphael Pelossof (Tempus)

The research team analyzed the Tempus multimodal real-world database to validate an RNA-seq-based, in-house breast intrinsic subtype predictor based on PAM50 subtypes including: Basal, HER2-like, Luminal A, and Luminal B. The subtype predictor demonstrated significant prognostic value in the basal-subtype across all metastatic sites examined including lymph node, liver, lung, and bones, as well as HR+/HER2- and HR-/HER2- cohorts. This work highlights the significance of combining molecular subtypes with IHC-based diagnostics to fully characterize clinically relevant subpopulations and risk.

Schedule a meeting with us

We'll be in touch shortly.